Eli Lilly & Co. vs. Sarepta Therapeutics,, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | SRPT | |
|---|---|---|
| Market Cap | $1.09 trillion | $1.94 billion |
| Revenue (TTM) | — | $1.97 billion |
| Net Income (TTM) | — | $-136,725,000 |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | SRPT | |
|---|---|---|
| Price / Book | — | 1.27 |
| Price / Sales | — | 0.98 |
LLY and SRPT split the valuation factors evenly.
Profitability
| LLY | SRPT | |
|---|---|---|
| Net Margin | — | -6.93% |
| Return on Equity | — | -8.95% |
LLY and SRPT split the profitability factors evenly.
Risk & Sentiment
| LLY | SRPT | |
|---|---|---|
| Short Interest | 1.29% | 9.38% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SRPT overview, SRPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.